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Fig. Rates of myocardial infarction (MI) by treatment with antiplatelet and
statin medications across cardiac risk. ASA, Acetylsalicylic acid.
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Volume 60, Number 6 Abstracts 1721such factors are typically cited as relative contraindications to CEA instead of
carotid stenting. The ﬁndings of our study do suggest that patients who
require prolonged operation for hemostasis or other reasons may beneﬁt
if possible from intermittent release of intraoperative retraction in order to
prevent temporary cranial nerve palsy and that surgeons should exercise
particular caution in patients who require early reoperation after CEA.
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Introduction: Surgeon radiation dose during complex endovascular
procedures (CEPs) has not been well studied. We sought to characterize ra-
diation exposure to surgeons during CEPs based on procedure type, oper-
ator position, level of operator training, upper vs lower body exposure, and
the addition of protective shielding.
Methods: Optically stimulable, luminescent nanoDot (Landauer Inc)
detectors were used tomeasure radiation dose prospectively to surgeons during
CEPs. NanoDot dosimeters were placed outside the lead apron of the primary
and assistant operator at the left upper chest and left lower pelvis positions. For
each case, procedure type, reference air kerma (RAK), kerma area product
(KAP), the relative position of the operator, level of training of the fellow,
and presence or absence of external additional shielding devices were recorded.
Threepositionswere assignedon the right hand side of the patient in decreasing
relative proximity to the ﬂat panel detector (FPD) as A, B, and C, respectively.
Position A (main operator) was closest to the FPD. Position D was on the left
side of thepatient at thebrachial access site.NanoDotswere readusingaMicro-
star II medical dosimetry system (Landauer Inc) after every procedure. The
nanoDot dosimetry systemwas calibrated for scattered radiation in an endovas-
cular suite with a NIST-traceable solid state radiation detector (Piranha T20,
RTI). Comparative statistical analyses of nanoDot dose levels between cate-
gories was performed using analysis of variance with Tukey pairwise compari-
sons. Bonferroni correction was used for multiple comparisons.
Results: There were 415 nanoDot measurements with the following
case distribution: 16 thoracic endovascular aortic repairs or endovascular
aneurysm repairs, 18 fenestrated endovascular aneurysm repairs (FEVARs),
13 embolizations, 41 lower extremity, 10 ﬁstulograms, and 13 viscerals. The
mean operator dose for FEVARs was statistically higher than for other case
types (P < .03), 15 mSv at position A and 11 mSv at position B. For all case
types, positions A (8.7 6 2.7 mSv) and D (14.4 6 7.8 mSv) received statis-
tically higher effective doses than B (3.9 6 2.7 mSv; P < .001 or C (0 mGy).
However, the mean operator dose for position D was not statistically
different from position A. The addition of the lead skirt signiﬁcantly
decreased the lower body dose (33 6 3.4 mSv to 6.3 6 3.3 mSv) but not
the upper body dose (6.5 6 3.3 mSv to 5.7 6 2.2 mSv). The use of ceil-
ing-mounted shielding did not affect the nanoDot dose. There was no dif-
ference in the operator dose observed based on level of training when the
fellow was in position A. KAP was the better predictor of operator radiation
dose compared with RAK. The mean KAP for all cases was 330 Gycm2, and
the regression coefﬁcient for operator dose to KAP was 0.021 6
0.003 mSv/Gycm2 for position A and 0.015 6 0.003 mSv/Gycm2 for B.
Conclusions: Surgeon radiation dose during CEPs depends on case
type, operator position, and table skirt use, but not on the level of fellow
training. On the basis of this data, the primary operator could performw12
FEVARs per week and have an annual dose of <10 mSv, which would not
exceed lifetime occupational dose limits during a 35-year career. Excluding
FEVARs with the above case mix, the primary operator could performw40
CEPs per week and stay within regulatory limits. With practical case loads,
operator doses are relatively low and unlikely to exceed occupational limits.
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Introduction: Medical management (MM) with antiplatelet (AP)
and statin therapy is recommended for most patients undergoing vascularsurgery. We evaluated the preoperative use of these on postoperative
myocardial infarction (MI) in patients undergoing high-risk procedures
within the Vascular Quality Initiative (VQI).
Methods: We studied VQI patients undergoing elective suprainguinal
(n ¼ 3039) and infrainguinal bypass (n ¼ 8323) and open abdominal aortic
aneurysm repair (n ¼ 3007) from 2005 to 2014. We examined the use of
MM (AP or statin, or both) on postoperative MI and postoperative death.
Multivariable analyses were performed to identify factors associated with
preoperative MM use as well as and MI and MI/death rates across proce-
dures and cardiac risk strata (using Vascular Study Group of New England
cardiac risk criteria).
Results: Overall, most patients were on both AP and statin at the time
of surgery (56% vs 12% neither agent, 19% AP only, 17% statin only), and
MM was similar across procedure groups. Rates of MI were similar despite
MM strategy, with slightly higher rates in patients on both agents (neither
AP or statin, 2.4%; AP only, 2.6%; statin only, 2.8%; both, 3.7%; P ¼ .003).
MI increased with cardiac risk (1.8% vs 3.8% vs 6.5% for low, medium, and
high risk; P < .01). When MI was stratiﬁed by cardiac risk, MM did not
reduce MI rates and was slightly higher for patients on both agents (Fig).
After multivariable adjustment for MI, MM was not associated with reduced
MI compared with those on neither medication (AP only: odds ratio [OR],
1.0; 95% conﬁdence interval [CI], 0.6-1.5; statin only: OR, 0.9; 95% CI,
0.5-1.4; both agents, OR, 1.0; 95% CI, 0.7-1.5; P > .05 for all). Findings
were similar for combined outcome of MI/death. Finally, analysis demon-
strated that APs and statins were used more often in patients with known
cardiovascular risk factors.
Conclusions: These data conﬁrm that MI events are highly associated
with a patient’s estimated cardiac risk. However, lack of MM did not result
in higher rates of MI. It appears that higher-risk patients are currently
selected for MM in VQI but that this is not associated with reduced post-
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Introduction: Arrival heart rate (AHR) and heart rate control (HRC)
are known indicators of cardiovascular complications after cardiac surgery, but
there is little evidence of their role in predicting outcome after major vascular
surgery. The purpose of this study was to determine whether AHR and HRC
are predictive of mortality or major adverse cardiac events (MACE) after elec-
tive vascular surgery in the Vascular Quality Initiative (VQI).
Methods: The VQI data set was used to perform a retrospective anal-
ysis of patients undergoing elective infrainguinal bypass (IIB), suprainguinal
bypass (SIB), and open abdominal aortic aneurysm (AAA) repair (oAAA).
MACE was deﬁned as any postoperative myocardial infarction (POMI),
dysrhythmia, or congestive heart failure. Controlled HR was deﬁned as a
HR of <75 beats/min upon operating room arrival. HRC was determined
by taking the highest intraoperative HR-AHR. Procedure-speciﬁc MACE
